← Back to all signals
RESEARCH PAPER ANALYSIS

Cerebellar Time and Relative Time: A Comparator-Based Dynamical Timing Model and its Relevance to Psychopathology and Therapies.

Introduces a Comparator-Based Dynamical Timing (CDT) model that attributes subjective time distortions to altered cerebellar scaling of time (gain κ) and situates cerebellar comparator interactions with cortex and basal ganglia to explain timing abnormalities across psychiatric and…

PMID41979778
JournalCerebellum (London, England)
Publication Date2026-04-14
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Introduces a Comparator-Based Dynamical Timing (CDT) model that attributes subjective time distortions to altered cerebellar scaling of time (gain κ) and situates cerebellar comparator interactions with cortex and basal ganglia to explain timing abnormalities across psychiatric and…

WHY IT MATTERS

Research significance

Offers a mechanistic, testable framework linking cerebellar–basal ganglia timing dysfunction to PD-relevant motor and cognitive symptoms and suggests EEG biomarkers and TMS-based interventions that could be pursued in translational studies, though direct PD-specific molecular targets or clinical…

ABSTRACT

Source abstract

Time perception is fundamental to adaptive behavior, providing the scaffold for prediction, coordination, and learning. The cerebellum has long been recognized as a core hub for interval timing, yet its role extends beyond motor control to perceptual chronometry, reinforcement learning, and affective regulation. Here we introduce a novel framework, a Comparator-Based Dynamical Timing (CDT) model which describes distortions of subjective time as transformations that yield compression, dilation, and changes in temporal precision. In this account, subjective time is scaled by a gain factor κ. When κ > 1, subjective time dilates; when κ < 1, subjective time compresses. We synthesize convergent evidence from cerebellar anatomy, physiology, and computational modeling, and show how time distortions in psychiatric, neurodegenerative and neurodevelopmental disorders can be interpreted in the context of altered cerebellar temporal processing. We argue that cerebellar circuits operate in concert with cortical and basal ganglia oscillators in a comparator role, minimizing temporal deviation and maximizing precision. We propose that dysfunction across these interconnected networks contributes to distortions in subjective time perception observed in schizophrenia, bipolar disorder, depression, anxiety, post-traumatic stress disorder, autism spectrum disorder), and motor and movement disorders including Parkinson’s Disease. This framework provides a quantitative tool to predict and monitor the progression of psychiatric and neurodevelopmental/neurodegenerative disorders characterized by disrupted timing networks. Beyond diagnostic utility proposing an EEG-informed approach to track deviations in time perception, it also offers a translational platform for testing novel interventions, including non-invasive neuromodulation such as transcranial magnetic stimulation.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic